Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study

Ipilimumab in Melanoma Patients with Brain Metastasis: A Retro­spective Multicentre Evaluation of Thirty-eight Patients

(2014) M Konstantinou et al.   ACTA DERMATO-VENEREOLOGICA

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients with Metastatic Colorectal Cancer Treated with Irinotecan and Cetuximab

(2013) K. Skougaard et al.   JOURNAL OF NUCLEAR MEDICINE

Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

(2012) R. Dummer et al.   ANNALS OF ONCOLOGY

Patterns of Response in Patients with Pretreated Metastatic Melanoma who Received Ipilimumab 3 mg/kg in a European Expanded Access Program: Five Illustrative Case Reports

(2012) Sofie Wilgenhof et al.   CANCER INVESTIGATION

The role of early 18F-FDG PET/CT in prediction of progression-free survival after 90Y radioembolization: comparison with RECIST and tumour density criteria

(2012) I. Zerizer et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma

(2011) L.C. Hygino da Cruz et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Continued pemetrexed and platin-based chemotherapy in patients with malignant pleural mesothelioma (MPM): Value of 18F-FDG-PET/CT

(2010) Niklaus G. Schaefer et al.   EUROPEAN JOURNAL OF RADIOLOGY

Pseudoprogression in patients with malignant gliomas treated with concurrent temozolomide and radiotherapy: potential role of p53

(2010) Hyun-Cheol Kang et al.   JOURNAL OF NEURO-ONCOLOGY

Imaging of CTLA4 Blockade-Induced Cell Replication with 18F-FLT PET in Patients with Advanced Melanoma Treated with Tremelimumab

(2010) A. Ribas et al.   JOURNAL OF NUCLEAR MEDICINE

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

(2009) Anna Maria Di Giacomo et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Do We Need a Different Set of Response Assessment Criteria for Tumor Immunotherapy?

(2009) A. Ribas et al.   CLINICAL CANCER RESEARCH

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors

(2009) R. L. Wahl et al.   JOURNAL OF NUCLEAR MEDICINE

Immune Therapy for Cancer

(2008) Michael Dougan et al.   Annual Review of Immunology

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma

(2008) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY